文献速递产科母胎医学

胎儿游离DNA筛查意外检出母体恶性肿瘤

Incidental Detection of Maternal Malignancy by Fetal Cell-Free DNA Screening.
PubMed 文献 · Obstet Gynecol · 2022-06-07

本文综述胎儿游离DNA筛查中意外发现母体恶性肿瘤的相关问题。当筛查结果与胎儿诊断检测不一致,尤其提示多个非整倍体或单一常染色体单体时,需警惕潜在母体恶性肿瘤。目前尚无共识指南指导咨询与评估,实验室报告政策差异显著,建议检查前应告知意外发现可能,异常结果应说明胎儿或母体诊断可能并提供进一步评估选项。

要点

  • 多个非整倍体或单一常染色体单体且与胎儿诊断不一致时,需警惕母体恶性肿瘤。
  • 检查前应告知可能出现的意外发现或不可报告结果。
  • 异常结果应说明胎儿或母体诊断可能,并推荐胎儿诊断检测。

核心结论

  • 胎儿游离DNA筛查可能因母体恶性肿瘤出现假阳性,多个非整倍体或单一常染色体单体且与胎儿诊断不一致时风险增加。
  • 目前尚无共识指南指导因游离DNA检测担忧恶性肿瘤患者的咨询与评估。
  • 实验室在报告政策、术语及意外发现报告策略上差异显著。

研究设计与样本

  • 本文为综述,检索范围未在原文中明确报告。

主要发现

  • 母体恶性肿瘤已被报道为产前游离DNA筛查假阳性的原因。
  • 当结果与胎儿诊断检测不一致时,多个非整倍体或单一常染色体单体增加潜在母体恶性肿瘤的可能性。
  • 实验室在报告政策、术语及意外或偶然发现的报告策略和方法上差异显著。

关键数值与推荐

  • 多个非整倍体或单一常染色体单体且与胎儿诊断检测不一致时,需考虑潜在母体恶性肿瘤。
  • 检查前咨询应解释意外或非预期发现或不可报告结果的可能性。
  • 异常、非预期或不可报告结果时,检查后咨询应包括可能的胎儿或母体诊断(含恶性肿瘤)。
  • 应解释进一步评估和管理选项,包括推荐胎儿诊断检测。
  • 各种作者推荐的癌症风险评估医学检查基于共识、经验和专家意见。

临床怎么用

  • 开单实践者需了解所选实验室的政策,以提供充分的检查前和检查后遗传咨询。
  • 检查前咨询应解释意外或非预期发现或不可报告结果的可能性。
  • 异常、非预期或不可报告结果时,检查后咨询应说明可能的胎儿或母体诊断(含恶性肿瘤)。
  • 应解释进一步评估和管理选项,包括推荐胎儿诊断检测。
  • 癌症风险评估策略应结合患者对信息的需求、费用及家族和个人病史。

局限性

  • 目前尚无共识指南指导因游离DNA检测担忧恶性肿瘤患者的咨询与评估。
  • 各种作者推荐的癌症风险评估医学检查基于共识、经验和专家意见。
  • 持续研究和多学科合作对于确定该日益常见筛查检测复杂结果的最佳管理实践至关重要。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Cell-free DNA is an advancing technology with increasing applications in screening, diagnosis, and treatment for several disease processes. The shared physiologic, genetic, and epigenetic characteristics of placental physiology and tumor development have become apparent to both clinicians and researchers. Maternal malignancy has been reported as a cause of false-positive prenatal cell-free DNA screening results. The detection of multiple aneuploidies or a single autosomal monosomy increases the chance for an underlying maternal malignancy when the result is discordant with fetal diagnostic testing. There is currently no consensus guideline on counseling and evaluation of patients with concern for malignancy from cell-free DNA testing. Furthermore, laboratories differ significantly in reporting policies, terminology, and in reporting strategies and methods used for unexpected or incidental findings. The ordering practitioner is therefore tasked to understand the policies of their laboratory of choice to provide adequate pretest and posttest genetic counseling. In pretest counseling, the potential for incidental or unexpected findings or nonreportable results should be explained. With an abnormal, unanticipated, or nonreportable result, posttest counseling should include a description of possible fetal or maternal diagnoses, including malignancy. Health care professionals should explain options for further evaluation and management, including a recommendation for fetal diagnostic testing. The medical workup recommended by various authors to evaluate cancer risk is based on consensus, experience, and expert opinion. These strategies should incorporate the patient's desire for information, cost, and family and personal medical history. Ongoing research and multi-disciplinary collaboration in this area is critical to identify best practices in management of complex results from this increasingly common screening test.

来源:Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Rink BD, Stevens BK, Norton ME, et al. Incidental Detection of Maternal Malignancy by Fetal Cell-Free DNA Screening. Obstet Gynecol. 2022. PMID: 35849469. doi:10.1097/AOG.0000000000004833

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。